Old Web
English
Sign In
Acemap
>
authorDetail
>
Joanna Pye
Joanna Pye
Takeda Pharmaceutical Company
Cancer research
Medicine
GCC Antibody
in patient
Peptide
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
2021
Journal of Clinical Oncology
Scott N. Gettinger
Rudolf M. Huber
Dong-Wan Kim
Lyudmila Bazhenova
Karin Holmskov Hansen
Marcello Tiseo
Corey J. Langer
Luis Paz-Ares
Howard Jack West
Karen L. Reckamp
Glen J. Weiss
Egbert F. Smit
Maximilian J Hochmair
Sang-We Kim
Myung-Ju Ahn
Edward S. Kim
Harry J.M. Groen
Joanna Pye
Florin Vranceanu
D. Ross Camidge
Show All
Source
Cite
Save
Citations (0)
A phase 1 study of TAK-164, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) cancers expressing GCC.
2021
Journal of Clinical Oncology
Richard D. Kim
James M. Cleary
Alexis Diane Leal
Aparna Raj Parikh
David P. Ryan
Shining Wang
Brittany Bahamon
Neeraj Gupta
Aaron Moss
Joanna Pye
Harry H. Miao
Johanna C. Bendell
Show All
Source
Cite
Save
Citations (0)
1